Clinical Trial

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2007-12-11; most recent amendment 2026-02-03.
Status change: Recruiting → Active, Not Recruiting 2011-01-18
Trial Details
NCT Number NCT00572169
Lead Sponsor University of Arkansas
Conditions Multiple Myeloma
Enrollment 177 participants
Start Date 2006-11
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-05